Akoya Biosciences (Akoya Biosciences) Risk Assessment

View and export this data going back to 2021. Start your Free Trial

What is Akoya Biosciences Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Akoya Biosciences is: No Data: Cannot be evaluated.

Competitive Comparison of Akoya Biosciences's Risk Assessment

For the Medical Instruments & Supplies subindustry, Akoya Biosciences's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akoya Biosciences's Risk Assessment Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Akoya Biosciences's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Akoya Biosciences's Risk Assessment falls into.

Akoya Biosciences (NAS:AKYA) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Akoya Biosciences Risk Assessment Related Terms

Thank you for viewing the detailed overview of Akoya Biosciences's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Akoya Biosciences (Akoya Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Akoya Biosciences Inc (NAS:AKYA) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Campus Drive, 6th Floor, Marlborough, MA, USA, 01752

Website

https://www.akoyabio.com

Akoya Biosciences Inc is a life sciences technology company. It is delivering spatial biology solutions focused on transforming discovery and clinical research. The company offers the comprehensive, end-to-end solutions for high-parameter tissue analysis from discovery through clinical and translational research, enabling the development of more precise therapies for immuno-oncology and other drug development applications. The company has its geographical presence in North America, APAC and EMEA. It generates majority of the revenue from North America.

Executives

Brian Mckelligon	director, officer: President/CEO	100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752
Frederic Pla	officer: Chief Operating Officer	C/O GENOMIC HEALTH, INC., 101 GALVESTON DRIVE, REDWOOD CITY CA 94063-4700
Goldman Myla Lai	director	3595 JOHN HOPKINS COURT, SAN DIEGO CA 92121
John Frederick Ek	officer: Chief Financial Officer	5964 LA PLACE COURT, CARLSBAD CA 92008
Scott Mendel	director	5964 LA PLACE COURT, ADDRESS 2, CARLSBAD CA 92008
Matthew Winkler	director	C/O MIRNA THERAPEUTICS, INC., 2150 WOODWARD ST., SUITE 100, AUSTIN TX 78744
Thomas A. Raffin	director, 10 percent owner	C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AIMES IA 50010
Robert G Shepler	director
Jennifer Kamocsay	officer: General Counsel	100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01762
Joseph Driscoll	officer: Chief Financial Officer	5 DICARLO ROAD, HOPKINTON MA 01748
Nolan Garry Ph.d.	director	100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752
Thomas P Schnettler	director	800 NICOLLET MALL, J1012057, MINNEAPOLIS MN 55402-7020
Ehab El-gabry	officer: Chief Medical Officer	100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752
Marilee Moy	officer: Chief People Officer	100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752
Ramachandran Niro Ph.d	officer: Chief Business Officer	100 CAMPUS DRIVE, 6TH FLOOR, MARLBOROUGH MA 01752